Clinical Trial Update: Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating reversal of heparin in patients undergoing percutaneous coronary intervention was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Snippet

Sponsor: PolyMedix, Inc. | Conditions: Percutaneous Coronary Intervention, Coronary Artery Disease (CAD) | Phase 2 | Status: TERMINATED